FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891493574> ?p ?o ?g. }

• W2891493574 endingPage "1245" @default.
• W2891493574 startingPage "1235" @default.
• W2891493574 abstract "Background During the past decade, many patients had zotarolimus-eluting stents implanted, which had circular shape cobalt–chromium struts with limited radiographic visibility. The Resolute Onyx stent was developed to improve visibility while reducing strut thickness, which was achieved by using a novel composite wire with a dense platinum–iridium core and an outer cobalt–chromium layer. We did the first randomised clinical trial to assess the safety and efficacy of this often-used stent compared with the Orsiro stent, which consists of ultrathin cobalt–chromium struts. Methods We did an investigator-initiated, assessor-blinded and patient-blinded, randomised non-inferiority trial in an allcomers population at seven independently monitored centres in Belgium, Israel, and the Netherlands. Eligible participants were aged 18 years or older and required percutaneous coronary intervention with drug-eluting stents. After guide wire passage with or without predilation, members of the catheterisation laboratory team used web-based computer-generated allocation sequences to randomly assign patients (1:1) to either the Resolute Onyx or the Orsiro stent. Randomisation was stratified by sex and diabetes status. Patients and assessors were masked to allocated stents, but treating clinicians were not. The primary endpoint was target vessel failure at 1 year, a composite of cardiac death, target-vessel-related myocardial infarction, and target vessel revascularisation, and was assessed by intention to treat (non-inferiority margin 2·5%) on the basis of outcomes adjudicated by an independent event committee. This trial is registered with ClinicalTrials.gov, number NCT02508714. Findings Between Oct 7, 2015, and Dec 23, 2016, 2516 patients were enrolled, 2488 of whom were included in the intention-to-treat analysis (28 withdrawals or screening failures). 1243 participants were assigned to the Resolute Onyx group, and 1245 to the Orsiro group. Overall, 1765 (70·9%) participants presented with acute coronary syndromes and 1275 (51·2%) had myocardial infarctions. 1-year follow-up was available for 2478 (99·6%) patients. The primary endpoint was met by 55 (4·5%) patients in the Resolute Onyx group and 58 (4·7%) in the Orsiro group. Non-inferiority of Resolute Onyx to Orsiro was thus established (absolute risk difference −0·2% [95% CI −1·9 to 1·4]; upper limit of the one-sided 95% CI 1·1%; pnon-inferiority=0·0005). Definite or probable stent thrombosis occurred in one (0·1%) participant in the Resolute Onyx group and nine (0·7%) in the Orsiro group (hazard ratio 0·11 [95% CI 0·01–0·87]; p=0·0112). Interpretation The Resolute Onyx stent was non-inferior to Orsiro for a combined safety and efficacy endpoint at 1-year follow-up in allcomers. The low event rate in both groups suggests that both stents are safe, and the very low rate of stent thrombosis in the Resolute Onyx group warrants further clinical investigation. Funding Biotronik and Medtronic. During the past decade, many patients had zotarolimus-eluting stents implanted, which had circular shape cobalt–chromium struts with limited radiographic visibility. The Resolute Onyx stent was developed to improve visibility while reducing strut thickness, which was achieved by using a novel composite wire with a dense platinum–iridium core and an outer cobalt–chromium layer. We did the first randomised clinical trial to assess the safety and efficacy of this often-used stent compared with the Orsiro stent, which consists of ultrathin cobalt–chromium struts. We did an investigator-initiated, assessor-blinded and patient-blinded, randomised non-inferiority trial in an allcomers population at seven independently monitored centres in Belgium, Israel, and the Netherlands. Eligible participants were aged 18 years or older and required percutaneous coronary intervention with drug-eluting stents. After guide wire passage with or without predilation, members of the catheterisation laboratory team used web-based computer-generated allocation sequences to randomly assign patients (1:1) to either the Resolute Onyx or the Orsiro stent. Randomisation was stratified by sex and diabetes status. Patients and assessors were masked to allocated stents, but treating clinicians were not. The primary endpoint was target vessel failure at 1 year, a composite of cardiac death, target-vessel-related myocardial infarction, and target vessel revascularisation, and was assessed by intention to treat (non-inferiority margin 2·5%) on the basis of outcomes adjudicated by an independent event committee. This trial is registered with ClinicalTrials.gov, number NCT02508714. Between Oct 7, 2015, and Dec 23, 2016, 2516 patients were enrolled, 2488 of whom were included in the intention-to-treat analysis (28 withdrawals or screening failures). 1243 participants were assigned to the Resolute Onyx group, and 1245 to the Orsiro group. Overall, 1765 (70·9%) participants presented with acute coronary syndromes and 1275 (51·2%) had myocardial infarctions. 1-year follow-up was available for 2478 (99·6%) patients. The primary endpoint was met by 55 (4·5%) patients in the Resolute Onyx group and 58 (4·7%) in the Orsiro group. Non-inferiority of Resolute Onyx to Orsiro was thus established (absolute risk difference −0·2% [95% CI −1·9 to 1·4]; upper limit of the one-sided 95% CI 1·1%; pnon-inferiority=0·0005). Definite or probable stent thrombosis occurred in one (0·1%) participant in the Resolute Onyx group and nine (0·7%) in the Orsiro group (hazard ratio 0·11 [95% CI 0·01–0·87]; p=0·0112). The Resolute Onyx stent was non-inferior to Orsiro for a combined safety and efficacy endpoint at 1-year follow-up in allcomers. The low event rate in both groups suggests that both stents are safe, and the very low rate of stent thrombosis in the Resolute Onyx group warrants further clinical investigation." @default.
• W2891493574 created "2018-09-27" @default.
• W2891493574 creator A5002284163 @default.
• W2891493574 creator A5025617105 @default.
• W2891493574 creator A5031934775 @default.
• W2891493574 creator A5034235902 @default.
• W2891493574 creator A5034680904 @default.
• W2891493574 creator A5034792349 @default.
• W2891493574 creator A5036459841 @default.
• W2891493574 creator A5036599056 @default.
• W2891493574 creator A5038626392 @default.
• W2891493574 creator A5045476126 @default.
• W2891493574 creator A5058093407 @default.
• W2891493574 creator A5062151964 @default.
• W2891493574 creator A5062318295 @default.
• W2891493574 creator A5064887206 @default.
• W2891493574 creator A5065394674 @default.
• W2891493574 creator A5070034270 @default.
• W2891493574 creator A5083182600 @default.
• W2891493574 date "2018-10-01" @default.
• W2891493574 modified "2023-09-29" @default.
• W2891493574 title "Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial" @default.
• W2891493574 cites W152352541 @default.
• W2891493574 cites W1527614413 @default.
• W2891493574 cites W1921048136 @default.
• W2891493574 cites W1997760014 @default.
• W2891493574 cites W2009328296 @default.
• W2891493574 cites W2009589924 @default.
• W2891493574 cites W2036113234 @default.
• W2891493574 cites W2040538327 @default.
• W2891493574 cites W2055057362 @default.
• W2891493574 cites W2087150869 @default.
• W2891493574 cites W2121006070 @default.
• W2891493574 cites W2124385743 @default.
• W2891493574 cites W2125716797 @default.
• W2891493574 cites W2129811129 @default.
• W2891493574 cites W2129970474 @default.
• W2891493574 cites W2133272102 @default.
• W2891493574 cites W2143566938 @default.
• W2891493574 cites W2144552468 @default.
• W2891493574 cites W2149623073 @default.
• W2891493574 cites W2150914344 @default.
• W2891493574 cites W2156613502 @default.
• W2891493574 cites W2462991524 @default.
• W2891493574 cites W2546366038 @default.
• W2891493574 cites W2547759268 @default.
• W2891493574 cites W2735498768 @default.
• W2891493574 cites W2742835916 @default.
• W2891493574 cites W2747702104 @default.
• W2891493574 cites W2749851477 @default.
• W2891493574 cites W2780381540 @default.
• W2891493574 cites W2810314526 @default.
• W2891493574 cites W3014766400 @default.
• W2891493574 doi "https://doi.org/10.1016/s0140-6736(18)32001-4" @default.
• W2891493574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30253879" @default.
• W2891493574 hasPublicationYear "2018" @default.
• W2891493574 type Work @default.
• W2891493574 sameAs 2891493574 @default.
• W2891493574 citedByCount "100" @default.
• W2891493574 countsByYear W28914935742018 @default.
• W2891493574 countsByYear W28914935742019 @default.
• W2891493574 countsByYear W28914935742020 @default.
• W2891493574 countsByYear W28914935742021 @default.
• W2891493574 countsByYear W28914935742022 @default.
• W2891493574 countsByYear W28914935742023 @default.
• W2891493574 crossrefType "journal-article" @default.
• W2891493574 hasAuthorship W2891493574A5002284163 @default.
• W2891493574 hasAuthorship W2891493574A5025617105 @default.
• W2891493574 hasAuthorship W2891493574A5031934775 @default.
• W2891493574 hasAuthorship W2891493574A5034235902 @default.
• W2891493574 hasAuthorship W2891493574A5034680904 @default.
• W2891493574 hasAuthorship W2891493574A5034792349 @default.
• W2891493574 hasAuthorship W2891493574A5036459841 @default.
• W2891493574 hasAuthorship W2891493574A5036599056 @default.
• W2891493574 hasAuthorship W2891493574A5038626392 @default.
• W2891493574 hasAuthorship W2891493574A5045476126 @default.
• W2891493574 hasAuthorship W2891493574A5058093407 @default.
• W2891493574 hasAuthorship W2891493574A5062151964 @default.
• W2891493574 hasAuthorship W2891493574A5062318295 @default.
• W2891493574 hasAuthorship W2891493574A5064887206 @default.
• W2891493574 hasAuthorship W2891493574A5065394674 @default.
• W2891493574 hasAuthorship W2891493574A5070034270 @default.
• W2891493574 hasAuthorship W2891493574A5083182600 @default.
• W2891493574 hasBestOaLocation W28914935742 @default.
• W2891493574 hasConcept C126322002 @default.
• W2891493574 hasConcept C141071460 @default.
• W2891493574 hasConcept C168563851 @default.
• W2891493574 hasConcept C203092338 @default.
• W2891493574 hasConcept C2777546689 @default.
• W2891493574 hasConcept C2778213512 @default.
• W2891493574 hasConcept C2778583881 @default.
• W2891493574 hasConcept C2780400711 @default.
• W2891493574 hasConcept C2780797203 @default.
• W2891493574 hasConcept C2908647359 @default.
• W2891493574 hasConcept C500558357 @default.
• W2891493574 hasConcept C71924100 @default.
• W2891493574 hasConcept C99454951 @default.
• W2891493574 hasConceptScore W2891493574C126322002 @default.

• next